SR 146131
Alternative Names: SSR-146131Latest Information Update: 23 Feb 2004
At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Cholecystokinin A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Drug-induced dyskinesia; Obesity
Most Recent Events
- 23 Feb 2004 Discontinued - Phase-I for Obesity in France (unspecified route)
- 23 Feb 2004 Discontinued - Preclinical for Drug-induced dyskinesia in France (unspecified route)
- 02 Oct 2002 Phase-I clinical trials in Obesity in France (unspecified route)